Is TJKB11 worth it? Analysis of TJK Renda Imobiliária FII

Recommendation: ACCUMULATE · Rating 6.9/10

Analysis and recommendation

TJKB11 is one of the few Brazilian REIT-style funds (FIIs) in Brazil with an exclusive mandate in healthcare — encompassing roughly 40 hospital and clinical properties spread across São Paulo, Joinville, and Rio de Janeiro, all with long-term leases (average term of 11 years) adjusted for inflation. Physical occupancy is 100% and the distribution remains at R$ 2.90 per unit per month, yielding roughly 13–14% per year on the current market price. The fund trades below its book value, representing a discount of about 10%. The main points of attention are: (1) two groups of properties with payment delays in 2026 — the larger one was resolved in installments (ending Oct/2026), while the smaller one (Neolink properties) was a one-off postponement in June; (2) very low average daily trading volume (~R$ 77k/day), limiting large positions; and (3) part of the current distribution comes from installment capital gains that will run out by the end of 2026. This fund is suitable as a small position (3–5% of the portfolio) for investors seeking healthcare sector diversification with inflation protection.

Investment thesis

TJKB11 is one of the rarest pure-play healthcare exposures in the Brazilian real-estate-fund (FII) market (HCRI11, NSLU11, HUSC11, HSRE11, and TJKB11 make up the entire universe). The fund delivers: 100% atypical leases with an 11.45-year WAULT, 100% sustained occupancy, IPCA-linked adjustments preserving the real value of the distribution, and real growth in net assets through acquisitions (R$ 200M in 2022 to R$ 604M as of Mar/2026). The 13.7% dividend yield offers a significant premium over the 14.5% Selic, Brazil's policy rate, considering the tax exemption for individual investors. The investment thesis for new buyers relies on: (1) the resilience of the healthcare sector; (2) the conversion of the new Instituto do Sono properties into stable revenue starting in Apr/2026; and (3) delinquency across 4 properties (Marselhesa, Tatuapé, Av. Brasil, and Borba Gato), which the Q2/2026 Quarterly Report lists at 0%—installments are current, with the payment plan running through Oct/2026. Critical bottlenecks shift: low liquidity (R$ 77k/day in May/26) remains structural, and capital gains from the Oct/2024 sale have CONCLUDED (final installment of R$ 15M received in Q2/2026). With the number of units doubling to 2,134,524 in the 1H2026 offering, the R$ 2.90 DPU now depends exclusively on recurring operating revenue—rental revenue for the quarter (~R$ 5.44M/month) still falls short of the ~R$ 6.19M/month required, a gap the fund must close with the Instituto do Sono and the new properties. The P/BV appears attractive (0.90), but reflects a book value that incorporates a recent fair-value adjustment (+R$ 40M in 2025).

Who it's for

  • Investors seeking rare sector exposure to healthcare (not found in hybrid FIIs)
  • Moderate-to-aggressive profile with a 5-10 year horizon
  • Investors willing to accept low liquidity in exchange for an 11.45-year WAULT with IPCA protection
  • Investors who actively monitor counterparties (the financial capacity of hospital tenants)
  • Satellite position (up to ~3-5% of an FII portfolio) for sector diversification

Who it's not for

  • Retirees needing predictable month-to-month DPU (the recent cut from R$ 2.90 to R$ 2.50 in Mar/26 highlights vulnerability)
  • Investors who need to enter or exit positions above R$ 200 thousand (insufficient volume)
  • Investors wanting strong geographic diversification (55% in São Paulo, 24% in Joinville)
  • Beginners without the capacity to assess the financial health of hospital operators (Oncoclínicas, AFYA, etc.)
  • Investors looking for credit (paper) or logistics FIIs—TJKB11 is a single-sector brick-and-mortar fund

Points of attention and risks

Delinquency of the 4 properties normalized — but cycle only ends in Oct/2026

The Q2/2026 Quarterly Report (ended June 30, 2026) reports 0% delinquency and 0% vacancy across ALL properties, including the four that experienced delays in Mar/2026 (Marselhesa, Tatuapé, Av. Brasil, and Borba Gato). The delay confirmed in the Material Fact Notice of March 17, 2026, has been paid in monthly installments ending in October/2026; contract status has returned to current. Risk has not entirely vanished until the installment plan concludes, but severity drops from high to medium. The DPU, cut to R$ 2.50 in Mar/26, had already returned to R$ 2.90 in Apr/26.

Capital gains from the Oct/2024 sale have ended — DPU now relies solely on operations with double the unit count

Q2/2026 records the cash receipt of the FINAL installment from the October 2024 property sale (R$ 15.0M), closing the capital gains cycle that had been supporting part of the distribution. At the same time, the number of units doubled (from 1,164,647 to 2,134,524) due to the offering carried out in H1 2026. Rental revenue for the quarter totaled R$ 16.3M (~R$ 5.44M/month); paying R$ 2.90 per unit across 2,134,524 units would require ~R$ 6.19M/month in earnings, a gap of ~R$ 0.75M/month previously covered by capital gains and earnings from the BRC-III Brazilian REIT-style fund (FII) (R$ 23.4M). With the R$ 15M exhausted, maintaining a R$ 2.90 DPU depends exclusively on recurring operational revenue — requiring Instituto do Sono and the properties added in the offering to generate sufficient cash to close this gap.

Low liquidity (~R$ 77k/day, May/26)

Average volume over the last 21 trading sessions around R$ 77 thousand — incompatible with positions above R$ 500 thousand. The 252-day average rises to R$ 389 thousand due to isolated higher-turnover months, but current trading conditions remain tight. Only 648 unitholders in Q1 2026 explain the structural issue.

Geographic concentration in São Paulo (55% of GLA)

55% of GLA is located in the city of São Paulo (Vila Mariana 35%, Santo Amaro 10%, Tatuapé 8%, Jardim Paulista 2%, Vila Olímpia 1%), 24% in Joinville (Centro de Tratamento de Olhos), 11% in Pompeia (via BRC-III fund), 9% in Rio de Janeiro. A local regulatory shock (São Paulo Healthcare) would impact a significant share of revenue.

Concentration in few tenants (single-tenant per property)

Each property has 1 tenant (single-tenant) — typical healthcare BTS/sale-and-leaseback model. Relevant concentration in IPEMED/AFYA (Barra Private + former Marselhesa), Oncoclínicas (Neolink + part of Barra), Instituto do Sono (3 new Vila Mariana properties, 16.6k sqm added in Mar/26). The departure of an anchor tenant would require re-leasing up to 30% of revenue.

P/BV is less discounted than it appears — book value carries recent write-ups

Book value per unit rose from R$ 265.69 (Dec/2024) to R$ 283.23 (Mar/2026) due to a R$ 40.2M fair value adjustment on properties appraised by Binswanger in Nov/2025. This positive adjustment increased the numerator (R$ 70.2M in 2025 accounting earnings vs R$ 25.8M in 2024) and inflates the book value. Auditor ECOVIS noted that certain property deeds (Ed. Mykonos, Neolink, Barra Private) are NOT YET registered in the Fund's name.

Light leverage via CRI (R$ 22.3M, 3.7% of net assets)

Two series of CRIs issued in Sep/2024 (Companhia Província Securitizadora — CRI 43), backed by leases of the Tatuapé (R$ 10M, CDI+4.35%) and Jardim Paulista (R$ 10M, IPCA+9.00%) properties. Amortization begins in Oct/2026. Maturities in Sep/2030 and Jan/2034. Reasonable average cost, but adds mismatch risk if property cap rates decline.

Is TJKB11 trustworthy?

Our current reading of TJKB11 is ACCUMULATE, with a score of 6.9/10. This score comes neither from the manager nor the administrator: it is Rico aos Poucos' editorial assessment, built from the documents the fund files with the CVM. Below is what supports it — and what argues against it.

Leads the bucket (1st/3). It is the only non-single-asset fund in the group: ~40 hospital and clinical properties, 100% of leases atypical (WAULT 11+ years) indexed to IPCA, and the highest dividend yield (~13.7%). While NSLU11 and HCRI11 depend on a single property/tenant (Rede D'Or), TJKB11 dilutes counterparty risk across dozens of assets while still delivering real net asset growth. It does not warrant a BUY rating because it has accumulated two cash-flow focuses (4 properties on installment plans through Oct/2026 + Neolink postponement), the capital gains that supported part of the DPU dried up in Q2/2026, and liquidity is extremely low (~R$ 77k/day). ACCUMULATE.

Is TJKB11 safe?

Safety in a REIT is not yes or no — it is how much risk you accept. TJKB11 has a medio risk profile. What that means in practice:

ComponentLevel
Concentração2.5
Price volatility2.5
Distribution volatility2.0
Liquidez4.5
Underlying asset risk3.5
Financial/leverage risk2.0

Risks that don't show up in TJKB11's fact sheet

Pending property deeds for 3 developments (Ed. Mykonos, Neolink, Barra Private)

ECOVIS auditors issued an EMPHASIS OF MATTER paragraph in the 2025 Audit Report indicating that certain property deeds do not yet reflect the transfer of ownership to the Fund's assets. By value: Ed. Mykonos (R$ 9.98M), Neolink (R$ 21.2M), and Barra Private (R$ 33.0M) total R$ 64M (10.5% of net assets).

Procedures underway; explanatory note 7 clarifies the status; an operational risk, not an ownership risk.

Single-tenant model per property requires retrofitting upon tenant departure

Each property is dedicated to 1 tenant (BTS/sale-and-leaseback) with specialized installations (surgery, oncology, ophthalmology). Anchor tenant departure requires significant retrofitting to re-lease—the secondary market for hospital real estate is narrow. An 11.45-year WAULT mitigates, but does not eliminate, the risk.

Atypical leases carry substantial termination penalties; tenants are well-capitalized (AFYA, Oncoclínicas).

Delinquency in Mar/2026 points to potential operational stress for the tenant(s)

4 properties (Marselhesa, Tatuapé, Av. Brasil, and Borba Gato) experienced payment delays in Mar/26, structured into 3 installments. These 4 properties account for ~13.5% of net assets. Simultaneous delinquency across 4 leases suggests a common issue (same tenant group? same sector under stress?). The material fact notice refers to 'tenant' in the singular—indicating potential hidden concentration.

Negotiation concluded with a payment plan; the manager did not signal risk of total default. Monitor the next 3 management reports.

Light leverage today turns into pressure in Oct/2026 (start of CRI principal amortization)

CRI 43 (Series 1: R$ 10M at CDI + 4.35% + Series 2: R$ 10M at IPCA + 9.00%) begins principal repayment in Oct/2026, spread over 48 and 88 installments, respectively. Additional cash outflows, even if small, pressure DPU if revenue from the Instituto do Sono fails to convert as projected.

The administrator may opt for early amortization depending on strategy.

Dilution from the 4th offering (units doubled in Mar/2026) could weigh on DPU

Units jumped from 1.16M to ~2.13M with the integration of the Instituto do Sono. The installment-based capital gain (R$ 13M over 12 months) is now diluted across significantly more units. If the real yield on the new properties falls below 10.52% p.a., DPU will decline structurally.

A 15-year atypical lease at R$ 2.38M/month indexed to IPCA covers debt service and generates a margin if actual revenue hits projections.

Neolink (Oncoclínicas RJ) with deferred payment in Jun/2026

Rental revenue from the Neolink properties was not received for the May/16-Jun/15 period. This adds a second set of cash flow problems beyond the 4 already delinquent properties. If Neolink also fails to regularize by Jul/26, the R$ 2.90 DPU will come under pressure even with installment-based capital gains offsetting it.

The manager stated this is a one-off deferral, not a delinquency. Adjustments were applied in June, signaling that the lease remains active.

Scenarios for TJKB11

ScenarioDescription
Full conversion of the Instituto do Sono in Oct/2026Stabilized collection from the 3 new Vila Mariana properties (R$ 2.38M/month, IPCA+) lifts DPU to R$ 3.00-3.15 and closes the discount to book value
Declining Selic rates open a window for discounted FIIsFocus survey projects Selic at 11% (May/2027). Long atypical FIIs typically reprice by +10-15% during easing cycles—TJKB11 could rise to R$ 280-290
Normalization of delinquency in Jun/2026Completion of the 3 regularization installments for the 4 delinquent properties confirms it was a one-off event—restoring confidence in a stable R$ 2.90 DPU
Delinquency deepens—tenant in the traditional SP block departsMarselhesa + Tatuapé + Av. Brasil + Borba Gato account for ~13% of net assets. If the delinquent tenant(s) enter total default, the impact on DPU is -R$ 0.40-0.50/unit until re-leasing (12-24 months)
Negative fair-value adjustment in the 2026 Binswanger appraisal reportThe Nov/2025 appraisal brought a +R$ 40M positive gain. In a rising cap rate cycle (high Selic + healthcare sector delinquency), the 2026 appraisal could reverse part of this gain, dropping book value per unit from R$ 283 to R$ 265-275—making the apparent P/BV less attractive
ANS/CRM health-regulator rules in São Paulo impact key operator55% of GLA is in São Paulo. Local regulatory changes (consultation pricing, accreditation requirements, oversight) affecting hospital operators (Oncoclínicas, AFYA, Instituto do Sono) could pressure rent-paying capacity

Conclusion

TJKB11 is a pure healthcare FII with a differentiated value proposition in the Brazilian market: 40 hospital and clinical assets in SP+SC+RJ, 100% long atypical leases (WAULT of 11.45 years), 95% inflation-linked, with 100% occupancy sustained for 4+ years. For investors seeking rare sector exposure (healthcare has only ~5 pure FIIs in the market), TJKB11 delivers on paper quality.

However, actual execution exposed two weaknesses in 2026: (1) delinquency in 4 properties in Mar/2026 (~13% of net assets) forced a DPU cut to R$ 2.50, with a regularization plan set in 3 installments through Jun/26; (2) cash flow mismatch between the 4th offering (3 Instituto do Sono properties acquired in Mar/26) and the start of revenue collection (Apr/26) precipitated the cut that same month. In Apr/26, the DPU returned to R$ 2.90.

The P/BV of 0.90 is not as extreme a discount as it appears at first glance. Book value was inflated by a R$ 40M fair value adjustment in the Binswanger appraisal in Nov/2025, and the auditor flagged in an emphasis of matter that title deeds for R$ 64M in properties (Mykonos, Neolink, Barra Private) have not yet been transferred to the fund. The 13.70% dividend yield is the highest in the hospital subsegment, but it reflects a risk premium for current delinquency and installment capital gains that run out in Dec/26.

Low liquidity (R$ 77k/day in May/26 with only 648 unitholders) is the primary constraint: TJKB11 does not fit portfolios with more than R$ 500k to allocate. For a satellite position (3–5% of an FII portfolio), it offers genuine sector diversification and inflation protection. For a retiree's core portfolio, the history of 3 DPU cuts in 4 years (Jun/23, Apr/25, Mar/26) is incompatible with the objective.

Frequently asked questions

Is TJKB11 good? Is it worth investing?

Current recommendation: ACCUMULATE. Rating 6.9/10. TJKB11 is one of the few Brazilian REIT-style funds (FIIs) in Brazil with an exclusive mandate in healthcare — encompassing roughly 40 hospital and clinical properties spread across São Paulo, Joinville, and Rio de Janeiro, all with long-term leases (average term of 11 years)…

TJKB11: buy or sell?

Our current read on TJKB11 is “ACCUMULATE”. Rating 6.9/10. Assess it against your risk profile and the points of attention listed above.

What are TJKB11's risks?

The main points of attention for TJK Renda Imobiliária FII include: Delinquency of the 4 properties normalized — but cycle only ends in Oct/2026; Capital gains from the Oct/2024 sale have ended — DPU now relies solely on operations with double the unit count; Low liquidity (~R$ 77k/day, May/26); Geographic concentration in São Paulo (55% of GLA).

Who is TJKB11 suitable for?

TJKB11 is suitable for: Investors seeking rare sector exposure to healthcare (not found in hybrid FIIs) Moderate-to-aggressive profile with a 5-10 year horizon Investors willing to accept low liquidity in exchange for an 11.45-year WAULT with IPCA protection